Biocon Biologics expands to over 70 countries, enters emerging markets

Completes integration of the acquired biosimilars business from Viatris

Biocon Biologics (BBL) has now taken the commercialisation of biosimilars business from Viatris in over 70 countries, thereby expanding the footprint in emerging markets.

BBL, a subsidiary of Biocon, has completed the integration of the acquired biosimilars business in over 70 countries effective July 1, the company said in a statement in Mumbai on  Wednesday. BBL had completed the acquisition of $3.34 billion Viatris’ global biosimilars business in November 2022.

Following the deal closure in November 2022, this marks the first wave of countries where Viatris operations have fully transitioned to BBL.

“The existing commercialized portfolio of biosimilars,